Glaukos Licenses RevOpsis Retina Biologic and Discovery Platform
Glaukos entered an exclusive agreement with RevOpsis Therapeutics to develop and commercialize RO-104, an investigational biologic for several retinal diseases. The candidate is designed to block VEGF-A, VEGF-C and Ang-2, while the agreement also lets Glaukos use RevOpsis technology to pursue up to four more retinal biologics. Glaukos shares fell after the announcement, with the reported decline varying by the time of the market update.
Why it matters
The license expands Glaukos' retinal development portfolio and gives it additional potential programs beyond RO-104. The financial terms were not disclosed, so the agreement's immediate economic impact cannot be assessed.
Key facts
- 1RO-104 is being developed for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. rttnews.com
- 2The biologic is designed to act on VEGF-A, VEGF-C and Ang-2 simultaneously. rttnews.com
- 3Glaukos received exclusive access to RevOpsis' RevMod technology for the potential creation of up to four further retinal biologic programs. theglobeandmail.com
- 4RevOpsis said the agreement's financial terms were not disclosed. theglobeandmail.com
Open questions
- The agreement's financial terms are undisclosed.
- The reported share-price declines differ across market updates because they reflect different reporting times or measurement windows.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.